Cavendish supported IXICO plc in its heavily oversubscribed placing and subscription, raising £4.0 million at a premium to the share price to build on its image analysis technology platform for the Alzheimer’s disease and Parkinson’s disease markets.

Giles Balleny, Corporate Finance Director at Cavendish, commented:

We are delighted to have assisted IXICO in securing this funding. This allows Bram and the team to accelerate the development and commercial reach of its technology platform for use in the Alzheimer’s disease and Parkinson’s disease markets and to develop additional biomarkers to assist in the break through research into neurological diseases.”